Incyte Genomics, Inc. v. Affymetrix, Inc.

I'll verify the party profiles, the accused technology, and the patent technical sketches before drafting, and I'll check the metadata contradictions flagged earlier.

Case overview & background

The parties — two Bay Area operating companies, not an NPE scenario. Incyte Genomics, Inc. (Palo Alto) was the 2000 rebranding of Incyte Pharmaceuticals, a genomics/bioinformatics company whose business was high-throughput cDNA sequencing monetized through subscription sequence databases (LifeSeq / LifeSeq Gold, ZooSeq, LifeExpress) sold to pharma, plus GEM microarray-based gene-expression services and genomic reagents/clone sets. (Incyte Form 10-Q Q1 2000, business overview — "database products, software, microarray-based gene expression services, and genomic reagents"; FY1998 10-K reporting ~$97.2M in R&D and revenue "primarily from database access fees"; https://incytecorp.gcs-web.com/static-files/ecb37e42-fdc4-423d-ab51-abc9245b7f6e.) It ran an aggressive patent program — reportedly 2,000+ applications covering ~11,000 full-length sequences (J. Storella, "A Bioinformatics Business Model and the Bold Patent Strategy Behind It: The Case of Incyte Genomics," ACI 5th Advanced Forum on Biotech Patents, 2005, http://www.wsgr.com/attorneys/NEWBIOS/PDFs/storella0905.pdf). Affymetrix, Inc. (Santa Clara) was the category-defining microarray company, selling GeneChip arrays made by light-directed, photolithographic in-situ synthesis (VLSIPS) and the instruments/software to read them. Both were operating companies with products at risk; the asymmetry is that Affymetrix was the patent plaintiff in 1998 and Incyte the later counter-puncher.

Accused technology and the patents. Incyte's theory, per its GC Lee Bendekgey, was that "Affymetrix has chosen to use, and to induce its customers to use, this fundamental intellectual property without a license" — i.e., that Affymetrix's expression-analysis products and its customers' sample-preparation workflow practiced Incyte's linear ("Eberwine"/aRNA) RNA-amplification patents, which Incyte held as exclusive licensee from Layton Bioscience. (BioProcess Online, 2000-08-22; Incyte 10-K "Legal Proceedings.") One-line technical sketches:

Procedural posture, venue, and why it matters. The case was filed in the Northern District of California and assigned to Judge Jeremy Fogel as C 01-20065 JF, docketed and litigated as a related action to Affymetrix's transferred 1998 array suits (C 99-21164/21165 JF) and to Incyte/Stanford's §146 appeal (C 99-21111 JF, 131 F. Supp. 2d 1154) — the caption of the December 2001 dismissal stipulation reads "AND RELATED ACTIONS." Venue was functionally inevitable and strategically significant: both parties were headquartered in the district (Palo Alto and Santa Clara), the Delaware-filed array suits had already been transferred there, and one judge therefore controlled claim construction across the entire microarray cluster — including Affymetrix v. Hyseq — so the January/May/June 2001 Markman rulings in that cluster, not anything in C 01-20065 itself, set the terms on which this case settled. The case is notable for four reasons: (i) it is a chapter in the 2000–01 microarray patent wars (Affymetrix v. Synteni/Incyte, Hyseq, Oxford Gene Technology), resolved by a cross-license plus $4.5M paid by Affymetrix as past Eberwine/Layton damages; (ii) it is an operating-company v. operating-company fight, but the patents-in-suit reached Incyte through an academic spin-out exclusive license (Eberwine/Van Gelder, U. Penn work, commercialized via Layton) — the university-tech-transfer licensing pattern, not PAE assertion; (iii) there is no IPR linkage to analyze — the AIA did not exist in 2001, so the parallel administrative track was BPAI Interference Nos. 104,358/104,359 and EPO oppositions; and (iv) the '934 itself later traveled through ex parte reexamination 90/008,675 (filed 2007-06-25; certificate US 5,445,934 C1 issued 2009-04-21), long after this case closed (https://patentimages.storage.googleapis.com/d9/17/63/91a6c7748f0925/US5445934.pdf), and expired in 2012. Market context: Incyte announced on 2001-10-25 that it was exiting microarrays (≈$55.6M restructuring, ~400 positions), renamed itself Incyte Corporation in December 2002 and abandoned the database/patent-licensing strategy — the settlement is effectively the closing act of that business model.

Sourcing caveats (flagging, not resolving)

• Metadata conflict, again. The case metadata describes a "declaratory-judgment action" asserting only 5,445,934. Primary documents show an Incyte-initiated infringement suit on the '785/'636 amplification patents (later '170), with the array patents entering only via Affymetrix counterclaims ('928, '193). The '934 was the lead patent of the companion C 99 cases. I could not retrieve a C 01-20065 docket sheet to test whether any DJ count or '934 count was actually pleaded — so the metadata's label and single-patent list remain unverified, not refuted.
• Filing-date tension. The "C 01-" numbering implies a 2001 filing; Incyte's SEC disclosure says the suit was filed in August 2000. Both are documented; I cannot reconcile them without the docket.
• Unverified in this pass: the titles/scopes of the '928 and '193 patents, and the division assignment (I refer to Judge Fogel's San Jose calendar as likely but have not confirmed the division designation from a filing).
• Not re-covered here (see the earlier sections): counsel of record, the Markman/SJ chronology, and the settlement's terms and carve-outs.

I'll research this case. Note upfront: this is a 2001 case, and I'll verify what's actually documented versus what's inferred.

Strong primary sources found. Let me dig into the docket history and the related Affymetrix cases.

Let me nail down the docket specifics and the companion-case history.

Incyte Genomics, Inc. v. Affymetrix, Inc., C 01-20065 JF (N.D. Cal.) — Chronology of Legal Developments

Source-quality note up front. This is a 2001 case that settled globally after ~15 months. There is no published opinion bearing the C 01-20065 caption, no trial, no verdict, and no appeal. The dossier below is reconstructed from (a) SEC filings and the filed Settlement Agreement/Stipulation of Dismissal (primary documents, quoted verbatim in the sources), (b) contemporaneous press releases and trade-press coverage, and (c) the claim-construction opinion in the consolidated Affymetrix array cases (Affymetrix v. Hyseq/Incyte), which is where the substantive patent rulings actually occurred. Where I could not verify a fact — most importantly, the C 01-20065 docket sheet itself, which I could not retrieve — I say so rather than fill the gap.

---

1. The predicate dispute (1998–1999): the case that C 01-20065 grew out of

C 01-20065 was the third of four N.D. Cal. proceedings between these parties before Judge Jeremy Fogel. The first two were Affymetrix's affirmative suits:

Affymetrix itself describes the settlement as ending "existing patent infringement litigation between the two companies that began in January 1998." (Affymetrix Form 8-K, filed 2001-12-28, reporting event of 2001-12-21, https://capedge.com/filing/[913077](/patent/913077)/0000912057-01-[544895](/patent/544895)/AFFX-8K.)

---

2. The Incyte-initiated action — filing and pleadings

This is the case numbered C 01-20065 JF, and it was Incyte's affirmative case, not a defensive declaratory-judgment action.

• Filing (date in tension — see caveat): Incyte's own SEC filings state that "[i]n August 2000, the Company filed a patent infringement suit against Affymetrix in the United States Court for the Northern District of California. The suit alleges infringement of the U.S. Patent Numbers 5,716,785 and 5,891,636." (Incyte Form 10-K, "Legal Proceedings," https://capedge.com/filing/s3-content/0001021408-01-[505179](/patent/505179)/1.) Contemporaneous trade press confirms the filing: "Incyte Genomics files two patent infringement suits," BioProcess Online, 2000-08-22 (suits against Gene Logic and Affymetrix).
• Patents asserted by Incyte: the '785 and '636 patents — the Eberwine / Layton linear RNA-amplification patents (inventors James H. Eberwine, Russell N. Van Gelder, Mark E. Von Zastrow, Jack D. Barchas), exclusively licensed to Incyte by Layton Bioscience. By the time of settlement, Incyte had added U.S. Pat. 6,291,170, which the Settlement Agreement defines as an "Incyte Patent-In-Suit."
• Theory of infringement: that "Affymetrix has chosen to use, and to induce its customers to use, this fundamental intellectual property without a license," per Incyte GC Lee Bendekgey. (BioProcess Online, 2000-08-22.)
• Affymetrix's counterclaims — the source of the '934/array nexus: Affymetrix "has filed counterclaims against the Company" in Incyte's suit, asserting U.S. Pat. 5,871,928 and U.S. Pat. 6,040,193 (two additional microarray patents). (Incyte Form 10-K, supra; reporting the second lawsuit as involving "the Company's RNA amplification patents … and two additional microarray-related patents held by Affymetrix (U.S. Patent Nos. 5,871,928 and 6,040,193)".) Incyte's suit sought a permanent injunction, damages, costs, fees and interest; Affymetrix's counterclaims sought the same plus treble damages for willfulness.

Discrepancy you should know about: the case-summary metadata renders C 01-20065 as "Incyte-initiated declaratory-judgment action" and lists only 5,445,934 as at issue. The primary documents support "Incyte-initiated," but the relief pleaded was infringement, not declaratory judgment, and the patents Incyte put at issue were the '785/'636 (plus '170). The '934 and its siblings ('305, '992) belonged to the companion C 99-21164/21165 cases — those defendants' own 10-K language treats our case as the "second lawsuit" in which the array patents entered only via Affymetrix counterclaims ('928 and '193). I could not retrieve the C 01-20065 docket sheet from PACER/RECAP through the tools available, so I cannot confirm whether an amended or separate declaratory-judgment count was pleaded. Treat the metadata's "declaratory judgment" label and single-patent list as unverified.

Second discrepancy: the "C 01-" prefix indicates a 2001 filing year, while Incyte's SEC disclosure says the suit was filed in August 2000. The "C 99-" companion cases were likewise renumbered on transfer. Both datapoints are documented; I cannot reconcile them from the sources available. Do not state the filing date as settled fact without pulling the docket sheet.

Consolidation. The Stipulation and Order of Dismissal is captioned Affymetrix, Inc. v. Synteni, Inc. and Incyte Pharmaceuticals, Inc., Nos. C 99-21164 (JF), C 99-21165 (JF), and C 01-20065 (JF) — "AND RELATED ACTIONS" — confirming that C 01-20065 was treated as a related action and resolved jointly with the earlier two. (Stipulation and [Proposed] Order of Dismissal, https://investor.incyte.com/static-files/a27a51c2-e0f7-4fcf-b7de-8a1c21addaa3.)

Counsel of record (from the protective order signature blocks; some names are OCR-degraded):

• Incyte / Synteni / Incyte Pharmaceuticals: Howrey Simon Arnold & White LLP — Robert P. Taylor, Teresa M. Corbin, Don F. Livornese (Menlo Park); Shearman & Sterling also appears on the stipulation.
• Affymetrix: Irell & Manella LLP — Morgan Chu, Richard de Bodo, Jeffrey L. Arrington (Los Angeles).

---

3. Claim construction (Markman) — the substantive rulings

No § 3-1 claim-construction order for C 01-20065 itself is publicly reported. The Markman work on the asserted array patents happened in the consolidated array litigation (Affymetrix v. Hyseq, Inc. and the C 99 Incyte cases, Judge Fogel), and it drove the settlement value:

2001-01-24 — First Markman ruling (reported 2001-01-25). Incyte publicized it as a win:

• '934 "discrete, known region" and '305 "predefined region" construed as "identified localized areas on a surface which are … activated for formation of a polymer, where the activation is accomplished through exposure of the localized area to an energy source." (Press release, via SiliconInvestor archive, 2001-01-25; BioCentury, "Markman ruling on arrays," 2001-01-25, https://www.biocentury.com/article/22987/markman-ruling-on-arrays.)
• Effect per Incyte: Affymetrix's claims reach only photolithographically (VLSIPS) synthesized arrays, not spotted/printed cDNA arrays like Incyte's.
• '992 — "a mixture of labeled nucleic acid from the two cell types" construed to require nucleic acids collected from the two cell types, so cDNA made in vitro falls outside the claim.
• The court rejected Incyte's attempt to import enablement limits (VLSIPS, monomer-by-monomer synthesis) into the claims, holding that a court "do[es] not have authority to redraft claims" to preserve validity — Process Control Corp. v. Hydreclaim; du Pont v. Phillips Petroleum. See Affymetrix, Inc. v. Hyseq, Inc. (N.D. Cal. 2001) (Fogel, J.), https://www.courtlistener.com/opinion/[2457323](/patent/2457323)/affymetrix-inc-v-hyseq-inc/.
• Terms construed to plain meaning over both defendants' narrower proposals: "oligonucleotide" (length sufficient to be useful), "polynucleotides" (polymer of nucleotides of length two or more), "determinable sequence" (a sequence that can be determined), and "detecting nucleic acid sequences" (presence/absence detection, not limited to sequencing).

2001-05-02 — Summary judgment of non-infringement. "Following issuance of the Court's January 2001 claim construction ruling, Incyte filed a motion for partial summary judgment … On May 2, 2001, the court granted summary judgement ruling that the Company's accused cDNA arrays do not infringe any claim of the '934 patent claims or claims 1 and 3 through 13 of the '305 patent." (Incyte 10-K, supra.)

2001-05-08 — Indefiniteness / invalidity of the '992 claims. "[T]he Court concluded that the term 'substantially complementary' as used in the '992 patent was indefinite and that claims in the '992 patent that use the term are therefore invalid." (Id.) The Germeshausen Center newsletter ("The Microarray Battle," https://www.ipmall.info/sites/default/files/hosted_resources/Germes_Newsletter/germeshausen-newsletter-01-sf.pdf) preserves the briefing on that term — Affymetrix relying on Regents of the Univ. of Cal. v. Oncor, Inc., 44 U.S.P.Q.2d 1321 (N.D. Cal. 1997) (Walker, J.), and on Incyte's own claim usage; Incyte replying on 2001-02-26 that "substantially" supplies no measurable standard.

2001-06 — Third claim-construction ruling in the '934/'305/'992 group. (Incyte 10-K: "In January, May, and June 2001, the Court issued three claims construction rulings describing how the claims in the '934, '305 and '992 patents should be interpreted.")

---

4. Discovery milestones of strategic significance

• Amended protective order extending the parties' confidentiality regime to C 01-20065: "Stipulation and Amended Protective Order for Confidential Documents, Testimony and Information in Cases C 99-21164, C 99-21165 and C 99-21111 and Amended Protective Order for Confidential Documents, Testimony and Information in Case C 01-20065." (Filed copy, https://investor.incyte.com/static-files/a27a51c2-e0f7-4fcf-b7de-8a1c21addaa3.) The two-tier structure (one protective order for the Affymetrix-initiated cases, a separate one for C 01-20065) is itself a tell that the parties were producing competitively sensitive Array/customer data and wanted segregated confidentiality treatment.
• Post-settlement carve-out: the parties expressly agreed that the '785/'636 RNA-amplification technology and the Accused Products were the subjects of substantial discovery in C 01-20065 — reflected in the releases, which reach customers, collaborators, agents and users of each side's microarray products, including "the use of data generated by" pre-effective-date products. (Settlement Agreement §§ 2.2–2.3, 3.2–3.3.)
• No discovery-conduct opinion, sanctions order, or discovery-dispute order in C 01-20065 is publicly reported that I can locate.

---

5. Pre-trial motion practice (July–August 2001) — all in the companion array cases

The dispositive-motion crunch that forced the global deal occurred in the C 99 cases, not C 01-20065:

• 2001-07-23 — Motion barrage. Incyte filed five partial summary-judgment motions: (i) invalidity of '992 claims 4 and 5 for lack of written description and indefiniteness; (ii) invalidity of the '305 patent for lack of written description; (iii) invalidity of '992 claims 1–3 for indefiniteness; (iv) non-infringement of '305; (v) non-infringement of '934. Affymetrix filed four: literal infringement of '305 claim 15; that '992 claims 4–5 are not invalid for lack of written description; literal infringement of '992 claims 4–5; and dismissal of Incyte's counterclaims.
• Hearing set for 2001-08-27. (Incyte 10-K, supra.)
• A case management conference was set for 2001-07-16 (Germeshausen newsletter, supra).
• No motion to dismiss, motion to transfer, motion to stay, or stay pending agency review is documented in C 01-20065. Note the anachronism: "stay pending IPR" is impossible in this case — see §8.

---

6. Trial events, verdict, post-trial motions

None. The case terminated before trial, before any verdict, and before any JMOL/new-trial/fee motion. The stipulation disposes of fees explicitly: "Each party shall bear its own attorneys' fees and costs of suit." (Stipulation ¶ 3.) No judgment on the merits, no injunction, no damages award, and no appeal as to C 01-20065.

---

7. Disposition: the 2001-12-21 global settlement

• 2001-12-21 — Settlement Agreement effective (Incyte–Affymetrix), accompanied by four related agreements: a cross-license/*** agreement, an internal-use license, and reciprocal patent licenses — described by the parties as "certain non-exclusive, royalty-bearing licenses and an internal use license under their respective intellectual property portfolios." (Settlement Agreement, https://www.lawinsider.com/contracts/b08QyAFTwcC; Incyte Form 8-K, 2001-12-21, https://investor.incyte.com/static-files/ba139110-a986-4633-898b-39656a0e8631.)
• 2001-12-21 — Dismissal with prejudice by stipulation, ordered by Judge Fogel that same day. "All claims, defenses, and counterclaims in Case Nos. C 99-21164, C 99-21165, and C 01-20065 are hereby dismissed with prejudice," with express non-admissions of validity/invalidity/enforceability and mutual reservation of issues. The court "retain[ed] jurisdiction over the implementation of the parties' settlement." (Stipulation, supra; Affymetrix 8-K, 2001-12-28.)
• Money term: Affymetrix paid Incyte $4.5 million at closing "as past damages with respect to Incyte's RNA amplification patents … the 'Eberwine' or 'Layton' patents," producing a one-time $4.5M charge in Affymetrix's Q4 2001. Incyte recorded the net cash settlement as revenue in 2001. Financial terms otherwise undisclosed.
• Releases: broad, with a Civil Code § 1542 waiver, running to affiliates and to downstream customers/users. Critically, Incyte's customer release expressly does not release Invitrogen Corporation (Settlement § 2.5) — preserving Incyte's then-pending S.D. Cal./D. Del. fights with Invitrogen on the same '785/'636 patents.
• Foreign/administrative terms: Incyte agreed to dismiss its EPO opposition to Affymetrix's EP 0 619 321.
• Carve-out: the settlement did not resolve the Stanford matters — i.e., C 99-21111 JF (Incyte/Stanford's de novo review of the BPAI decision on the '305/'992), the Stanford-related EPO/Australian oppositions (EP B1 0804731; AU 709276), and BPAI Interference Nos. 104,358 and 104,359. The Stipulation (¶ 4) states C 99-21111 "is not being settled or dismissed at this time," and the joint protective-order obligations ran until C 99-21111 terminated.
• Market context: Incyte had announced on 2001-10-25 that it was exiting microarray products/services (a ~$55.6M restructuring charge, ~400 positions), reducing its incentive to keep litigating array claims. Affymetrix, for its part, had settled with Oxford Gene Technology (March 2001, ~$19M) and with Hyseq in October 2001 on the same array patents.

Present posture: C 01-20065 is closed — dismissed with prejudice on 2001-12-21, with no appeal and no surviving claims. The only piece of the overall dispute that lived on was C 99-21111 (Stanford/Incyte v. Affymetrix). I have not located the final resolution of that petition for de novo review; by Incyte's FY2003 Form 10-K, the "Affymetrix" disclosure had dropped out of the litigation note entirely, which is consistent with full resolution, but I cannot confirm the outcome from the sources retrieved.

---

8. Parallel PTAB (IPR/PGR) proceedings

There are none, and there could not have been. The AIA's inter partes review did not exist until 2012-09-16; PGR/CBM likewise. In 2001 the only administrative patent challenge mechanisms were ex parte reexamination, EPO oppositions, and BPAI interferences — and that is exactly the track used here:

(Interference/petition list from the Settlement Agreement recitals, https://www.lawinsider.com/contracts/b08QyAFTwcC, and Affymetrix 8-K, 2001-12-28. Party names in the filed copy are redaction-redacted; the "… v. Stephen P.A. F[odor], et al." format and the Stanford/array subject matter point to the Stanford-side inventors, but I have not independently verified the named parties.)

Finally, as to the '934 patent specifically: filed 1992-09-30, issued 1995-08-29, it expired in 2012 — essentially contemporaneously with the first date IPR petitions could be filed. No IPR, PGR, or CBM was ever filed on U.S. Pat. 5,445,934, and none could be relevant to C 01-20065.

---

9. Bottom line for the case file

1. C 01-20065 was Incyte's offensive RNA-amplification case ('785, '636, later '170) against Affymetrix, consolidated with Affymetrix's 1998 array suits (C 99-21164/21165). Affymetrix counterclaimed on the '928 and '193 array patents.
2. All merits action was in the companion cases: the 2001-01-24 Markman ruling (limiting '934/'305 to energy-activated/photo-directed synthesis, and '992 to samples taken from the cells), the 2001-05-02 SJ of non-infringement of '934 and most of '305, and the 2001-05-08 holding that '992's "substantially complementary" claims are indefinite and invalid.
3. With nine summary-judgment motions pending and a 2001-08-27 hearing looming, the parties settled globally on 2001-12-21, dismissing C 01-20065 with prejudice by Judge Fogel's order the same day, cross-licensing portfolios, and moving $4.5M from Affymetrix to Incyte as past Eberwine/Layton damages.
4. No trial, no verdict, no JMOL, no fee motion, no appeal, no PTAB proceeding. The only post-settlement survival was the Stanford/Incyte C 99-21111 de novo review, expressly excluded from the release.

Verification gaps to close before relying on this externally: (i) the C 01-20065 docket sheet (filing date, whether a DJ count was pleaded, whether the case was renumbered from an August 2000 filing); (ii) the exact citation for the consolidated claim-construction opinion (Affymetrix, Inc. v. Hyseq, Inc., N.D. Cal. 2001, Fogel, J.; the Westlaw pagination in the retrieved text runs to *1218–19, but I did not confirm the reporter volume); (iii) the final disposition of C 99-21111 and Interference Nos. 104,358/104,359.

I'll research the docket and related filings for this case.

Now let me look for the docket sheet and any appearances specific to C 01-20065, plus background on the named counsel.

Bottom line

I could not pull a standalone PACER docket sheet for C 01-20065 JF (a 2001 N.D. Cal. case — it predates RECAP coverage and the N.D. Cal. civil docket for that era is not freely retrievable), so I cannot give you a docket-entry-by-docket-entry appearance list. However, the counsel of record for the plaintiff, Incyte Genomics, Inc., is affirmatively documented in a joint filing made in C 01-20065 — the Stipulation and [Proposed] Order of Dismissal entered by Judge Jeremy Fogel on December 21, 2001 in Affymetrix, Inc. v. Synteni, Inc., C 99-21164 JF / C 99-21165 JF, caption "AND RELATED ACTIONS," expressly covering C 01-20065 (JF). That stipulation states it is made "through their counsel of record" and lists two firms signing for Incyte.

Plaintiff's counsel of record — Incyte Genomics, Inc.

Note on the defendant's side (for contrast): the same stipulation lists Irell & Manella LLP (Morgan Chu, Richard de Bodo, Jeffrey L. Arrington, Los Angeles) for Affymetrix.

Important caveats

• "Lead" is inferred, not docket-verified. The stipulation does not label roles; I have assigned "lead" to Taylor based on his consistent first-listing in the related N.D. Cal. opinions and the Delaware transfer briefing. The actual ECF/paper appearance entries for C 01-20065 would be the definitive check and are not publicly retrievable here.
• Probable additional appearances I could not confirm for this case number: Bradley J. Olsen (Howrey Simon Arnold & White, Washington, D.C.) is listed for the Incyte/Stanford plaintiffs in 131 F. Supp. 2d 1154, and N. Thane Bauz, Jenifer A. Tipsord and Sharmini N. Green (Howrey, Menlo Park) appeared for Synteni/Incyte in the 1998–99 Delaware phase of Affymetrix v. Synteni. Whether any of them entered an appearance specifically in C 01-20065 is unverified.
• Firm-history note: Howrey Simon Arnold & White dissolved in 2011 (much of its Silicon Valley IP group went to Winston & Strawn); Shearman & Sterling has since combined into A&O Shearman. I mention this only so the firm names are not mistaken for current affiliations of these lawyers.
• No sealed-counsel issue is indicated. The December 2001 dismissal stipulation was filed publicly, and the settlement itself was disclosed in Incyte's and Affymetrix's SEC filings, so there is no indication that plaintiff's counsel identity was under seal.

Primary sources: Stipulation and [Proposed] Order of Dismissal (Dec. 2001), reproduced as Exhibit A to the Incyte–Affymetrix Settlement Agreement of Dec. 21, 2001 (https://contracts.onecle.com/incyte/affymetrix.set.2001.12.21.shtml; https://www.lawinsider.com/contracts/b08QyAFTwcC); Incyte Pharms., Inc. v. Affymetrix, Inc., 131 F. Supp. 2d 1154 (N.D. Cal. 2000) (https://law.justia.com/cases/federal/district-courts/FSupp2/131/1154/[2579988](/patent/2579988)/); Affymetrix, Inc. v. Synteni, Inc. (D. Del. transfer opinion) (https://www.casemine.com/judgement/us/5914bb6fadd7b04934796a17); Incyte Form 8-K dated Dec. 28, 2001 and Incyte Form 10-Q (2002) litigation notes; "Shearman & Sterling boosts Silicon Valley with IP expert," The Lawyer; N.D. Cal. ADR neutral profile for Vicki S. Veenker.

I'll research the defendant's (Affymetrix's) counsel of record, verifying against the filings already identified and looking for additional appearances.

The Irell & Manella firm history confirms the representation. Now let me find the actual signature blocks and any additional appearances.

Defendant's counsel of record — Affymetrix, Inc.

Bottom line. Affymetrix was represented by its long-time outside patent trial firm, Irell & Manella LLP (Los Angeles). Three Irell attorneys are affirmatively documented as counsel of record in the very filings that bear the C 01-20065 caption — the Stipulation and Amended Protective Order for Confidential Documents, Testimony and Information in Case Nos. C 99-21164, C 99-21165, C 01-20065, and the [Proposed] Order of Dismissal, both of which list them as "[a]ttorneys for Affymetrix, Inc." against the caption block that includes "Civil Action No. C 01-20065 (JF)."

I could not retrieve a standalone PACER docket sheet for C 01-20065 (2001 N.D. Cal. case; predates RECAP coverage), so I cannot give an ECF-entry-by-entry appearance list, and I cannot see the full "OTHER COUNSEL LISTED ON SIGNATURE PAGE" set. What follows is grounded in the signature blocks of the joint filings.

---

Affirmatively documented counsel of record

All three are listed on the same signature block in the December 2001 dismissal stipulation and in the amended protective order — both of which expressly cover C 01-20065 (JF) alongside C 99-21164 and C 99-21165. The filings' own caption note "OTHER COUNSEL LISTED ON SIGNATURE PAGE" confirms additional Irell (and/or local) attorneys appeared whose names I could not extract from the retrieved text.

---

Caveats and verification gaps

• No local counsel identified. N.D. Cal. practice often pairs an out-of-district trial firm with Bay Area local counsel; Irell is an L.A. firm, so local counsel may have been added, but I found no such appearance and will not name one. This is a gap, not a negative finding.
• No in-house counsel identified. Neither the stipulation nor the protective order names an Affymetrix in-house attorney. I have not verified who held the GC role at Affymetrix in 2001, so I am not naming anyone.
• Firm address discrepancy to flag. The filed signature block reads "1880 Avenue of the Stars"; Irell & Manella's address is and was "1800 Avenue of the Stars, Suite 900." I read 1880 as an OCR/typo artifact in the Investor-Incyte-hosted copy — flagging it rather than silently correcting, per the sourcing rule.
• Contrast with plaintiff's side (already covered in the earlier section). Plaintiff Incyte/Synteni was represented by Howrey Simon Arnold & White LLP (Robert P. Taylor, Teresa M. Corbin, Don F. Livornese; Menlo Park) and Shearman & Sterling (Vicki S. Veenker) — the same stipulation lists both firms for the Incyte parties.
• Firm-history note. Irell & Manella remains an active firm; Morgan Chu and Richard de Bodo are still Irell partners. Nothing about the 2001 representation of Affymetrix should be read as their current client roster.

Primary sources. Stipulation and [Proposed] Order of Dismissal and Stipulation and Amended Protective Order (both covering C 99-21164/21165/C 01-20065 JF), reproduced in Incyte's investor filing (http://investor.incyte.com/static-files/a27a51c2-e0f7-4fcf-b7de-8a1c21addaa3); Irell & Manella representative-matters/Chambers profile confirming the firm's Affymetrix–Incyte representation (https://storage.courtlistener.com/recap/gov.uscourts.ded.37436.324.0.pdf; https://chambers.com/department/irell-manella-llp-intellectual-property-patent-litigation-usa-5:137:12059:1:3628); Incyte Pharms., Inc. v. Affymetrix, Inc., 131 F. Supp. 2d 1154 (N.D. Cal. 2000) (companion §146 matter) (https://law.justia.com/cases/federal/district-courts/FSupp2/131/1154/2579988/).

If you need the definitive appearance list, the remaining step is a manual PACER pull of the C 01-20065 docket (and the full signature pages of the two 2001 protective orders), since neither is freely retrievable through the tools available here.